Detalhe da pesquisa
1.
A strategy to identify housekeeping genes suitable for analysis in breast cancer diseases.
BMC Genomics
; 17(1): 639, 2016 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27526934
2.
Changes in the transcriptional profile in response to overexpression of the osteopontin-c splice isoform in ovarian (OvCar-3) and prostate (PC-3) cancer cell lines.
BMC Cancer
; 14: 433, 2014 Jun 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-24928374
3.
Both osteopontin-c and osteopontin-b splicing isoforms exert pro-tumorigenic roles in prostate cancer cells.
Prostate
; 72(15): 1688-99, 2012 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-22495819
4.
Positive crosstalk between EGFR and the TF-PAR2 pathway mediates resistance to cisplatin and poor survival in cervical cancer.
Oncotarget
; 9(55): 30594-30609, 2018 Jul 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-30093972
5.
Ion Channel and Neurotransmitter Modulators as Electroceutical Approaches to the Control of Cancer.
Curr Pharm Des
; 23(32): 4827-4841, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28554310
6.
Validation of a network-based strategy for the optimization of combinatorial target selection in breast cancer therapy: siRNA knockdown of network targets in MDA-MB-231 cells as an in vitro model for inhibition of tumor development.
Oncotarget
; 7(39): 63189-63203, 2016 Sep 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-27527857
7.
Osteopontin is a tumor autoantigen in prostate cancer patients.
Oncol Lett
; 2(1): 109-114, 2011 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-22870138
8.
Osteopontin-c splicing isoform contributes to ovarian cancer progression.
Mol Cancer Res
; 9(3): 280-93, 2011 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-21263033